-
14 October 2025
-
14 October 2025
Ipsen announces the conclusion of an agreement between its main shareholders representing 52.06% of the capital and 66.15% of the voting rights
PARIS, FRANCE, 14 OCTOBER 2025 - Ipsen (Euronext: IPN: ADR: IPSEY) announced today that its Board of Directors has been informed of the conclusion of a new agreement1 between Highrock (controlled by Anne Beaufour), Beech Tree (controlled by Henri Beaufour)...
-
18 May 2026
-
18 May 2026
Ipsen initiates a new share buy-back program
Ipsen initiates a new share buy-back program...
-
29 April 2024
- 0 mins read
-
29 April 2024
- 0 mins read
-
22 July 2026
-
22 July 2026
-
29 July 2026
-
29 July 2026
Ipsen nominates Catherine Bradley to its Board of Directors as independent Director
Ipsen appoints Catherine Bradley as independent Director to its Board of Directors ...
-
03 April 2026
-
03 April 2026
Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer
PARIS, FRANCE, 3 April 2026 — Ipsen (Euronext: IPN; ADR: IPSEY) announces that Beech Tree — which directly and indirectly holds 26.03% of Ipsen S.A.’s share capital and 33.05% of its voting rights — has obtained from the French Financial Markets A...
-
23 March 2026
-
23 March 2026
Ipsen provides clarifications regarding the succession of Mr. Henri Beaufour – Group governance agreement relating to Beech Tree*
PARIS, FRANCE, 23 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that Beech Tree, which holds directly and indirectly 26.03% of the share capital and 33.05% of the voting rights of Ipsen SA, announces that Altawin, Fondation Alasol and B...
-
28 May 2024
-
28 May 2024
Annual General Meeting of Ipsen S.A. held on 28 May 2024
PARIS, FRANCE, 28 May 2024 - The Annual General Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY) was held today at the Salons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France), under the chairmanship of Mr. Marc de GARIDEL, Cha...
-
15 December 2025
-
15 December 2025
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. ...
-
19 December 2025
-
19 December 2025
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia os...